Key Highlights
- SMMT shares fell 9.26% in today's session to $10.73 from a prior close of $11.82.
- The FDA issued a Complete Response Letter for the ivonescimab BLA.
- HARMONi met its PFS primary endpoint but showed no statistically significant overall survival result.
- The shares fell 16.5% on Monday on Volume roughly four times average.
Summit Therapeutics (NASDAQ:SMMT) shares fell again in today's session, extending a slide that followed the FDA's Complete Response Letter for ivonescimab. The stock was at $10.73, down 9.26% from the prior close of $11.82, on volume of about 9.9 million shares, and reached a new 52-week low. The 52-week range runs from $10.53 to $29.23.
The shares fell 16.5% on Monday to close at $11.82, on volume roughly four times average. Summit is a Miami-based, clinical-stage biopharmaceutical oncology company. Its lead candidate, ivonescimab, is a PD-1 x VEGF bispecific antibody licensed from Akeso for North America, South America, Europe, the Middle East, Africa and Japan. The company announced the FDA letter on November 15.
What Did the FDA Say in the Complete Response Letter?
The letter covers the BLA for ivonescimab with platinum-containing chemotherapy in locally advanced or metastatic non-small cell lung cancer after prior EGFR tyrosine kinase inhibitor therapy. The FDA indicated that the BLA cannot be approved in its present form because substantial evidence of effectiveness is not established without a statistically significant overall survival improvement. It added that a progression-free survival benefit without a significant overall survival benefit does not support a positive benefit-risk profile.
What Did the HARMONi Trial Show?
HARMONi is a global, randomized, double-blind Phase III trial in EGFR-mutated, non-squamous lung cancer previously treated with a third-generation EGFR inhibitor. It has two primary endpoints, progression-free survival and overall survival. The trial met its progression-free survival endpoint. The primary overall survival analysis showed a positive trend without reaching statistical significance, and a post-hoc analysis with longer follow-up showed a hazard ratio of 0.76 in the full population, Asian patients and western patients.
Sixteen patients (7.3%) discontinued ivonescimab because of treatment-related adverse events, versus 11 (5.0%) on placebo. Four patients (1.8%) in the ivonescimab arm and five (2.3%) in the chemotherapy-alone arm died from treatment-related events. Co-CEO Robert Duggan said the company is disappointed for patients and that nothing changes in its belief in ivonescimab, citing five positive Phase III studies between Summit and Akeso.
How Are Analysts Responding?
Analysts largely expected the rejection. Jefferies kept its Buy rating and $30 price target, calling the downside limited. Barclays cut its target to $18 from $20, saying the FDA bar may be higher for the lung program, and Citi trimmed its target to $42 from $43. Akeso shares fell sharply in Hong Kong.
HARMONi-3 Squamous Data and the Pipeline Set the Next Checkpoints
Investors are watching HARMONi-3 squamous data around year-end. Summit is running Phase II and Phase III trials in lung, colorectal, urothelial and renal cell cancers and collaborating with companies including Revolution Medicines (NASDAQ:RVMD) and GSK (NYSE:GSK) on combination studies.






Please wait processing your request...